Royalty Pharma Sub-Manager, LLC holds a concentrated book of 4 stocks worth $241.9M as of Q2 2026 (disclosed Aug 21, 2026, a ~52-day 13F lag). This quarter they opened Kailera Therapeutics. Their largest long position is Cytokinetics Inc at 35% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
78% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Royalty Pharma Sub-Manager, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 5 / 4 | $475.7M |
| Police & Firemen's Retirement System of New Jersey | 5 / 4 | $5.1M |
| Ameritas Investment Partners, Inc. | 5 / 4 | $3.7M |
| NISA INVESTMENT ADVISORS, LLC | 5 / 4 | $1.2M |
| Sterling Capital Management LLC | 5 / 4 | $233K |
| BlackRock, Inc. | 4 / 4 | $1.4B |
| FMR LLC | 4 / 4 | $910.3M |
| STATE STREET CORP | 4 / 4 | $860.7M |
Ranked by how many of Royalty Pharma Sub-Manager, LLC's top 4 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Cytokinetics, Inc COM | $83.5M | 980.4K | 34.5% | —Held | |
| 2 | Zenas Biopharma, Inc. COM | $60.6M | 2.39M | 25.1% | —Held | |
| 3 | Kailera Therapeutics COM | $54.1M | 2.46M | 22.4% | ▲New New position | |
| 4 | Biohaven Ltd COM | $43.7M | 2.94M | 18.1% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2081668/holdings"
Use Arkolith to show Royalty Pharma Sub-Manager, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 21, 2026 | 4 | $241.9M | 13F-HR/A |
| Q1 2026 | Mar 31, 2026 | Aug 21, 2026 | 4 | $172.8M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Aug 21, 2026 | 4 | $171.3M | 13F-HR/A |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.